Article Details

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of ...

Retrieved on: 2021-06-18 18:00:00

Tags for this article:

Click the tags to see associated articles and topics

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of .... View article details on hiswai:

Excerpt

Ublituximab is an investigational glycoengineered monoclonal antibody that ... Targeting CD20 using monoclonal antibodies has proven to be an ...

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up